|
Affiliation |
Faculty of Medicine College Hospital Department of radiology |
|
Title |
Assistant Professor |
|
External Link |
|
|
Related SDGs |
|
KADOTA Yoshihito
|
|
|
Papers 【 display / non-display 】
-
MAEDA Kenichi, KAWANO Tomoki, KIMOTO Yasuhiro, TAMURA Mitsuru, KADOTA Yoshihito, AZUMA Minako, KOJIMA Koutarou, OKITA Yoshiko, TSUKINO Takeru, YAMASHITA Shinji, KOMAKI Satoru
NMC Case Report Journal 13 ( 0 ) 69 - 75 2026
Language：English Publishing type：Research paper (scientific journal) Publisher：The Japan Neurosurgical Society
-
Cerebral radiation necrosis successfully treated with high-dose bevacizumab Reviewed
Kugimiya K., Tsubouchi H., Saito K., Kadota Y., Azuma M., Sakai K., Oda Y., Sumiyoshi M., Yanagi S., Miyazaki T.
Respiratory Medicine Case Reports 58 102282 2025.1
Language：English Publishing type：Research paper (scientific journal) Publisher：Respiratory Medicine Case Reports
Cerebral radiation necrosis (CRN) is a late complication that can occur after the treatment of a brain tumor with focal radiation therapy, particularly stereotactic radiosurgery (SRS). Since an excessive production of vascular endothelial growth factor (VEGF) from necrotic lesions is a possible etiology of radiation necrosis, the anti-VEGF antibody bevacizumab has been reported as an effective treatment option. We report a case of a 71-year-old Japanese male with CRN following SRS, successfully treated with bevacizumab. He had presented with aphasia and right lower-limb muscle weakness 6 years after a left upper lobectomy for lung adenocarcinoma. Head magnetic resonance imaging (MRI) showed a metastatic brain tumor in the left temporal lobe. A craniotomy and pre- and post-operative SRS treatments were performed to relieve his neurological symptoms. Although initial symptom improvement was observed, the patient developed lower-limb muscle weakness and aphasia symptoms 7 months after the last SRS treatment.<sup>11</sup>C-methionine positron emission tomography (PET) and<sup>18</sup>F-fluorodeoxyglucose PET scans showed no abnormal uptake, leading to a diagnosis of CRN. The patient was treated with bevacizumab 15 mg/kg every 3 weeks for six cycles. The bevacizumab treatment resulted in an improvement of neurological symptoms and lesions showing gadolinium-enhancing effects and high-signal areas on T2-weighted fluid attenuated inversion recovery on MRI. The improvement was maintained 44 months after the completion of the last bevacizumab treatment. Although no definitive number of cycles and dosage of bevacizumab for CRN have been established, this case suggests that administering six cycles of bevacizumab may prevent long-term recurrence of CRN.
-
KADOTA Yoshihito, ODA Yoshinao, AKIYAMA Yuri, AZUMA Minako, YAMASHITA Atsushi, OKITA Yoshiko, YAMASHITA Shinji, OGURI Nobuyuki, KAWANO Tomoki, AKIZUKI Keiichi, TOMONAGA Takumi, MATSUMOTO Fumitaka
NMC Case Report Journal 12 ( 0 ) 525 - 530 2025
Language：English Publishing type：Research paper (scientific journal) Publisher：The Japan Neurosurgical Society
-
Uetani H, Azuma M, Khant ZA, Watanabe Y, Kudo K, Kadota Y, Yokogami K, Takeshima H, Kuroda JI, Shinojima N, Hamasaki T, Mukasa A, Hirai T
Journal of computer assisted tomography 47 ( 4 ) 659 - 665 2023.2
Language：English Publishing type：Research paper (scientific journal) Publisher：Journal of Computer Assisted Tomography
Purpose This study aimed to investigate the most useful clinical and magnetic resonance imaging (MRI) parameters for differentiating isocitrate dehydrogenase (IDH)-mutant and-wildtype glioblastomas in the 2016 World Health Organization Classification of Tumors of the Central Nervous System. Methods This multicenter study included 327 patients with IDH-mutant or IDH-wildtype glioblastoma in the 2016 World Health Organization classification who preoperatively underwent MRI. Isocitrate dehydrogenase mutation status was determined by immunohistochemistry, high-resolution melting analysis, and/or IDH1/2 sequencing. Three radiologists independently reviewed the tumor location, tumor contrast enhancement, noncontrast-enhancing tumor (nCET), and peritumoral edema. Two radiologists independently measured the maximum tumor size and mean and minimum apparent diffusion coefficients of the tumor. Univariate and multivariate logistic regression analyses with an odds ratio (OR) were performed. Results The tumors were IDH-wildtype glioblastoma in 306 cases and IDH-mutant glioblastoma in 21. Interobserver agreement for both qualitative and quantitative evaluations was moderate to excellent. The univariate analyses revealed a significant difference in age, seizure, tumor contrast enhancement, and nCET (P < 0.05). The multivariate analysis revealed significant difference in age for all 3 readers (reader 1, odds ratio [OR] = 0.960, P = 0.012; reader 2, OR = 0.966, P = 0.048; reader 3, OR = 0.964, P = 0.026) and nCET for 2 readers (reader 1, OR = 3.082, P = 0.080; reader 2, OR = 4.500, P = 0.003; reader 3, OR = 3.078, P = 0.022). Conclusions Age and nCET are the most useful parameters among the clinical and MRI parameters for differentiating IDH-mutant and IDH-wildtype glioblastomas.
-
Yamashita S., Takeshima H., Kadota Y., Azuma M., Fukushima T., Ogasawara N., Kawano T., Tamura M., Muta J., Saito K., Takeishi G., Mizuguchi A., Watanabe T., Ohta H., Yokogami K.
Brain Tumor Pathology 39 ( 2 ) 88 - 98 2022.4
Language：English Publishing type：Research paper (scientific journal) Publisher：Brain Tumor Pathology
After the new molecular-based classification was reported to be useful for predicting prognosis, the T2-fluid-attenuated inversion recovery (FLAIR) mismatch sign has gained interest as one of the promising methods for detecting lower grade gliomas (LGGs) with isocitrate dehydrogenase (IDH) mutations and chromosome 1p/19q non-codeletion (IDH mut-Noncodel) with high specificity. Although all institutions could use T2-FLAIR mismatch sign without any obstacles, this sign was not completely helpful because of its low sensitivity. In this study, we attempted to uncover the mechanism of T2-FLAIR mismatch sign for clarifying the cause of this sign’s low sensitivity. Among 99 patients with LGGs, 22 were T2-FLAIR mismatch sign-positive (22%), and this sign as a marker of IDH mut-Noncodel showed a sensitivity of 55.6% and specificity of 96.8%. Via pathological analyses, we could provide evidence that not only microcystic changes but the enlarged intercellular space was associated with T2-FLAIR mismatch sign (p = 0.017). As per the molecular analyses, overexpression of mTOR-related genes (m-TOR, RICTOR) were detected as the molecular events correlated with T2-FLAIR mismatch sign (p = 0.020, 0.030. respectively). Taken together, we suggested that T2-FLAIR mismatch sign could pick up the IDH mut-Noncodel LGGs with enlarged intercellular space or that with overexpression of mTOR-related genes.
Books 【 display / non-display 】
-
特集：時系列から学ぶ中枢神経疾患の画像診断 −MR Retroscopy−
東 美菜子、門田善仁、平井俊範（ Role： Joint author）
株式会社学研メディカル秀潤社 2020.8
Total pages：1154 Responsible for pages：1048-1051 Language：Japanese Book type：Scholarly book
-
知っておきたい顎・歯・口腔の画像診断
門田善仁、平井俊範（ Role： Joint author）
学研メディカル秀潤社 2017.7
Total pages：368 Responsible for pages：250-251,254-255,256-257 Language：Japanese Book type：Scholarly book
MISC 【 display / non-display 】
-
特集 時系列から学ぶ中枢神経疾患の画像診断-MR Retroscopy- Ⅱ.天幕上(大脳)A. 脳実質内? 脳実質外? 2 前頭部正中の嗅索と連続する腫瘤
東 美菜子, 門田 善仁, 平井 俊範
画像診断 40 ( 10 ) 1048 - 1051 2020.8
Publishing type：Rapid communication, short report, research note, etc. (scientific journal) Publisher：学研メディカル秀潤社
-
特集：脳梗塞超急性期診療 ２．脳梗塞超急性期の画像診断 CT － Advanced Neuro Imaging －
門田善仁、平井俊範
日獨医報 62 ( 2 ) 20 - 28 2018.1
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (scientific journal) Publisher：バイエル薬品
-
特集 MRIのT2・FLAIR画像での白質高信号の意味を読み解く
平井俊範、東美菜子、門田善仁
精神医学 59 ( 7 ) 619 - 625 2017.7
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media) Publisher：医学書院
-
CASE OF THE MONTH,CASE OF January Invited
門田善仁、平井俊範
画像診断 37 ( 1 ) 91 - 91 2016.12
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media) Publisher：株式会社学研メディカル秀潤社
-
特集 脳腫瘍WHO2016 －読影のための実践講座－ 松果体部腫瘍 Invited
門田善仁、平井俊範
画像診断 36 ( 13 ) 1284 - 1292 2016.10
Language：Japanese Publishing type：Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media) Publisher：株式会社学研メディカル秀潤社
Presentations 【 display / non-display 】
-
末梢神経に生じたメトトレキサート関連リンパ増殖性疾患（MTX-LPD）の1例
松村 研吾、門田 善仁、東 美菜子、金丸 和樹、塩見 一剛、岩尾 浩昭
第195回日本医学放射線学会九州地方会
Event date： 2022.6.18 - 2022.6.19
Language：Japanese Presentation type：Oral presentation (general)
-
頭部IVR 後に出現した高吸収域の原因判別における2層検出器スペクトラルCTの有用性の初期経験
服部洋平、東 美菜子、門田 善仁、平井俊範、竹島秀雄
第49回日本神経放射線学会
Event date： 2020.6.10 - 2020.6.30
Language：Japanese Presentation type：Oral presentation (general)
-
静脈洞血栓症における単純MRI 撮像法の診断能の比較検討：全国多施設共同研究
東 美菜子、渡邉嘉之、門田善仁、横上聖貴、竹島秀雄、平井俊範
第49回日本神経放射線学会
Event date： 2020.6.10 - 2020.6.30
Language：Japanese Presentation type：Oral presentation (general)
-
ASLにて両側基底核に高灌流を認めた尿毒症性脳症の一例
東 美菜子、門田善仁、Zaw Aung Khant、服部洋平、平井俊範
第49回日本神経放射線学会
Event date： 2020.6.10 - 2020.6.30
Language：Japanese Presentation type：Oral presentation (general)
-
頭頚部膿瘍の診断における２層検出器スペクトラルCTの有用性の検討
井手貴一、東 美奈子、門田善仁、平井俊範
第190回日本医学放射線学会九州地方会 (佐賀県佐賀市)
Event date： 2020.2.8 - 2020.2.9
Language：Japanese Presentation type：Oral presentation (general)
Venue：佐賀県佐賀市